What will pharma look like in 2020?

Drug Discovery World

Volumn 8, Issue 3, 2007, Pages 9-16

  Arlington, Steve ^a  

^a Pharmaceutical and Life Sciences Advisory Services

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE MANAGEMENT; HEALTH INSURANCE; MEDICAL PRACTICE; PRESCRIPTION; PRODUCT DEVELOPMENT;

EID: 34547531474     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. In 2006, the member companies of Pharmaceutical Research and Manufacturers of America spent $43 billion on R&D - nearly three times the $15.2 billion they spent on R&D in 1995, and more than twice the $19.84 billion this sum would now be worth when adjusted for inflation. However, the US Food and Drug Administration approved only 22 new molecular entities in 2006, compared with the 53 it approved in 1995.
2. PricewaterhouseCoopers. "Pharma 2020:TheVision, Which Path Will You Take" Oune 2007), available at http://www.pwc.com/pharma.
3. World Health Organisation. "Preventing chronic disease:A vital investment" (2005), accessed April 26, 2007, http://www.who.int/chp/ chronic_disease_report/part1/en/index.html.
4. Atun, Rifat and Gurol-Urgania, Ipek. "Impact of Regulation on the Uptake and Diffusion of Pharmaceutical Innovations: Systematic Review", International Journal of Innovation Management, Vol. II (2007), pp. 299-321.
5. In a survey of the attitudes of oncologists by Dr Eric Nadler, a researcher at Harvard Medical School, about 80% of the respondents said that they would prescribe a drug costing up to $70,000, even if it could only extend a patienes life by two months more than the standard treatment. For further information, see Alex Berenson, "Cancer Drugs Offer Hope, but at a Huge Expense", The New York Times (July 12, 2005), accessed April 26, 2007, http://www.nytimes.com/2005/07/12/ business/12cancer.html?ex=1278820800&en=1eb889752ca5eb49&ei= 5088&partner=rssnyt&emc=rss.
6. Allen, Mike. "Bush Touts Plan for Electronic Medicine" The Washington Post (May 28, 2004), accessed April 26, 2007, http://www.washingtonpost.com/wp-dyn/articles/A61772-2004May27.html.
7. BBC News. "Electronic care records go ahead" (18 December 2006), accessed April 26, 2007, http://news.bbc.co.uk/1/hi/health/ 6184043.stm.
8. The Centers for Medicare and Medicaid Services reports that the US spent $1.99 trillion on healthcare in 2005, and that $200.7 billion went on prescription drugs. Information accessed April 26, 2007, http://www.cms.hhs.gov/NationalHealthExpendData/ 02_NationalHealthAccountsHistorical.asp#TopOfPage.
9. Australia, Belgium, Canada, Cuba, England, France, Hong Kong, India, Ireland, Italy, Montenegro, New Zealand, Norway, Scotland, Sweden, Singapore, Uruguay and Wales have introduced nationwide bans on smoking in enclosed public places. A number of US states have introduced similar rules. For further information, see BBC News, "Smoking curbs:The global picture" Oanuary 31, 2007), accessed April 26, 2007, http://news.bbc.co.uk/1/hi/world/3758707.stm.
10. Associated Press. "European health ministers approve anti-obesity charter". International Herald Tribune Europe (November 16, 2006), accessed April 26, 2007, http://www.iht.com/articles/ap/2006/11/16/ europe/EU_MED_Anti_Obesity_Charter.php.
11. UK Department of Health. "Our health, our care, our say: a new direction for community services". (January 2006), accessed April 26, 2007, http://www.dh.gov.uk/assetRoot/04/12/74/59/04127459.pdf.
12. US National Science Foundation. "Science and Engineering Indicators 2006", accessed April 26, 2007, http://www.nsf.gov/statistics/ seind06/c2/c2s4.htm.
13. Patrick McAndrews. "Lilly Sings A New Tune: Chorus Unit Brings High Efficiency Note To Early R&D", The Pink Sheet, Vol. 69, No. 009, p. 26.
14. Trusheim, Mark R, Berndt, Ernst R et al. "Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers". Nature Reviews Drug Discovery, Vol. 6 (April 2007), pp. 287-293, accessed May 1, 2007, http://www.nature.com/nrd/journal/v6/n4/ full/nrd2251.html;jsessionid=D411A21FF180A6D04F8ES30BFA39CA3C.
15. Davies, Nicholas and Henderson, Stuart. "Drugs, devices, and the promise of pervasive computing". Current Drug Discovery (October 2003), pp. 25-28.
16. "In-life testing" is the use of remote monitoring devices to track how patients respond to medicines in a real-life setting rather than the rarefied environment of clinical trials. This concept was first articulated in the IBM Global Business Services paper "Pharma 2010: The threshold of innovation" (2002), accessed April 26, 2007, http://www-935.ibm.com/services/de/bcs/pdf/2006/pharma_2010.pdf.
17. The European Medicines Agency authorised the use of conditional approvals for orphan drugs and therapies for life-threatening conditions in April 2006 under Regulation EC 507/2006.The US Food and Drug Administration is piloting the concept under the Prescription Drug User Fee Act (PDUFA) III.
18. OECD, "Health at a Glance: OECD Indicators 2005".